MR Imaging Characteristics and ADC Histogram Metrics for Differentiating Molecular Subgroups of Pediatric Low-Grade Gliomas

References

1. 1.↵
   1. Ostrom QT,
   2. de Blank PM,
   3. Kruchko C, et al

   . Alex’s Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. Neuro Oncol 2015;16(Suppl 10):x1–36 doi:10.1093/neuonc/nou327 pmid:25542864

   CrossRefPubMed
2. 2.↵
   1. Komori T

   . The 2016 WHO Classification of Tumours of the Central Nervous System: the major points of revision. Neurol Med Chir (Tokyo) 2017;57:301–11 doi:10.2176/nmc.ra.2017-0010 pmid:28592714

   CrossRefPubMed
3. 3.↵
   1. Wisoff JH,
   2. Sanford RA,
   3. Heier LA, et al

   . Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children’s Oncology Group. Neurosurgery 2011;68:1548–54; discussion 1554–55 doi:10.1227/NEU.0b013e318214a66e pmid:21368693

   CrossRefPubMedWeb of Science
4. 4.↵
   1. AlRayahi J,
   2. Zapotocky M,
   3. Ramaswamy V, et al

   . Pediatric brain tumor genetics: what radiologists need to know. Radiographics 2018;38:2102–22 doi:10.1148/rg.2018180109 pmid:30422762

   CrossRefPubMed
5. 5.↵
   1. Szudek J,
   2. Birch P,
   3. Riccardi VM, et al

   . Associations of clinical features in neurofibromatosis 1 (NF1). Genet Epidemiol 2000;19:429–39 doi:10.1002/1098-2272(200012)19:4<429::AID-GEPI13>3.0.CO;2-N pmid:11108651

   CrossRefPubMed
6. 6.↵
   1. Helfferich J,
   2. Nijmeijer R,
   3. Brouwer OF, et al

   . Neurofibromatosis type 1 associated low grade gliomas: a comparison with sporadic low grade gliomas. Crit Rev Oncol Hematol 2016;104:30–41 doi:10.1016/j.critrevonc.2016.05.008 pmid:27263935

   CrossRefPubMed
7. 7.↵
   1. Vuong HG,
   2. Altibi AM,
   3. Duong UN, et al

   . BRAF mutation is associated with an improved survival in glioma-a systematic review and meta-analysis. Mol Neurobiol 2018;55:3718–24 doi:10.1007/s12035-017-0599-y pmid:28534272

   CrossRefPubMed
8. 8.↵
   1. Mistry M,
   2. Zhukova N,
   3. Merico D, et al

   . BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol 2015;33:1015–22 doi:10.1200/JCO.2014.58.3922 pmid:25667294

   Abstract/FREE Full Text
9. 9.↵
   1. Karajannis MA,
   2. Legault G,
   3. Fisher MJ, et al

   . Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro Oncol 2014;16:1408–16 doi:10.1093/neuonc/nou059 pmid:24803676

   CrossRefPubMed
10. 10.↵
    1. Ho CY,
    2. Mobley BC,
    3. Gordish-Dressman H, et al

    . A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation. Acta Neuropathol 2015;130:575–85 doi:10.1007/s00401-015-1467-3 pmid:26264609

    CrossRefPubMed
11. 11.↵
    1. Ramaglia A,
    2. Tortora D,
    3. Mankad K, et al

    . Role of diffusion weighted imaging for differentiating cerebral pilocytic astrocytoma and ganglioglioma BRAF V600E-mutant from wild type. Neuroradiology 2020;62:71–80 doi:10.1007/s00234-019-02304-y pmid:31667545

    CrossRefPubMed
12. 12.↵
    1. Rodriguez Gutierrez D,
    2. Awwad A,
    3. Meijer L, et al

    . Metrics and textural features of MRI diffusion to improve classification of pediatric posterior fossa tumors. AJNR Am J Neuroradiol 2014;35:1009–15 doi:10.3174/ajnr.A3784 pmid:24309122

    Abstract/FREE Full Text
13. 13.↵
    1. Bull JG,
    2. Saunders DE,
    3. Clark CA

    . Discrimination of paediatric brain tumours using apparent diffusion coefficient histograms. Eur Radiol 2012;22:447–57 doi:10.1007/s00330-011-2255-7 pmid:21918916

    CrossRefPubMed
14. 14.↵
    1. Parmar C,
    2. Rios Velazquez E,
    3. Leijenaar R, et al

    . Robust radiomics feature quantification using semiautomatic volumetric segmentation. PLoS One 2014;9:e102107 doi:10.1371/journal.pone.0102107 pmid:25025374

    CrossRefPubMed
15. 15.↵
    1. van Griethuysen JJ,
    2. Fedorov A,
    3. Parmar C, et al

    . Computational radiomics system to decode the radiographic phenotype. Cancer Res 2017;77:e104–07 doi:10.1158/0008-5472.CAN-17-0339 pmid:29092951

    Abstract/FREE Full Text
16. 16.↵
    1. Ishi Y,
    2. Yamaguchi S,
    3. Yoshida M, et al

    . Correlation between magnetic resonance imaging characteristics and BRAF alteration status in individuals with optic pathway/hypothalamic pilocytic astrocytomas. J Neuroradiol 2021;48:266–270 doi:10.1016/j.neurad.2019..05.006 pmid:31228537

    CrossRefPubMed
17. 17.↵
    1. Wagner MW,
    2. Hainc N,
    3. Khalvati F, et al

    . Radiomics of pediatric low-grade gliomas: toward a pretherapeutic differentiation of BRAF-mutated and BRAF-fused tumors. AJNR Am J Neuroradiol 2021;42:759–765 doi:10.3174/ajnr.A6998 pmid:33574103

    Abstract/FREE Full Text
18. 18.↵
    1. Ryall S,
    2. Tabori U,
    3. Hawkins C

    . Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun 2020;8:30 doi:10.1186/s40478-020-00902-z pmid:32164789

    CrossRefPubMed
19. 19.↵
    1. Lee S,
    2. Choi SH,
    3. Ryoo I, et al

    . Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. J Neurooncol 2015;121:141–50 doi:10.1007/s11060-014-1614-z pmid:25205290

    CrossRefPubMed
20. 20.↵
    1. Lee MK,
    2. Park JE,
    3. Jo Y, et al

    . Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign. Eur Radiol 2020;30:844–54 doi:10.1007/s00330-019-06395-2 pmid:31446467

    CrossRefPubMed
21. 21.↵
    1. Koh DM,
    2. Collins DJ

    . Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007;188:1622–35 doi:10.2214/AJR.06.1403 pmid:17515386

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Guo AC,
    2. Cummings TJ,
    3. Dash RC, et al

    . Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002;224:177–83 doi:10.1148/radiol.2241010637 pmid:12091680

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Doskaliyev A,
    2. Yamasaki F,
    3. Ohtaki M, et al

    . Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T. Eur J Radiol 2012;81:339–44 doi:10.1016/j.ejrad.2010.11.005 pmid:21129872

    CrossRefPubMed
24. 24.↵
    1. Calli C,
    2. Kitis O,
    3. Yunten N, et al

    . Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol 2006;58:394–403 doi:10.1016/j.ejrad.2005.12.032 pmid:16527438

    CrossRefPubMed
25. 25.↵
    1. Gihr G,
    2. Horvath-Rizea D,
    3. Hekeler E, et al

    . Diffusion weighted imaging in high-grade gliomas: a histogram-based analysis of apparent diffusion coefficient profile. PLoS One 2021;16:e0249878 doi:10.1371/journal.pone.0249878 pmid:33857203

    CrossRefPubMed
26. 26.
    1. Aboian MS,
    2. Tong E,
    3. Solomon DA, et al

    . Diffusion characteristics of pediatric diffuse midline gliomas with histone H3-K27M mutation using apparent diffusion coefficient histogram analysis. AJNR Am J Neuroradiol 2019;40:1804–10 doi:10.3174/ajnr.A6302 pmid:31694820

    Abstract/FREE Full Text
27. 27.↵
    1. Kang Y,
    2. Choi SH,
    3. Kim YJ, et al

    . Gliomas: histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging—correlation with tumor grade. Radiology 2011;261:882–90 doi:10.1148/radiol.11110686 pmid:21969667

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Lobon-Iglesias MJ,
    2. Laurendeau I,
    3. Guerrini-Rousseau L, et al

    . NF1-like optic pathway gliomas in children: clinical and molecular characterization of this specific presentation. Neurooncol Adv 2020;2:i98–106 doi:10.1093/noajnl/vdz054 pmid:32642735

    CrossRefPubMed
29. 29.↵
    1. Matsuoka A,
    2. Minato M,
    3. Harada M, et al

    . Comparison of 3.0-and 1.5-Tesla diffusion-weighted imaging in the visibility of breast cancer. Radiat Med 2008;26:15–20 doi:10.1007/s11604-007-0187-6 pmid:18236129

    CrossRefPubMed
30. 30.↵
    1. Saremi F,
    2. Jalili M,
    3. Sefidbakht S, et al

    . Diffusion-weighted imaging of the abdomen at 3 T: image quality comparison with 1.5-T magnet using 3 different imaging sequences. J Comput Assist Tomogr 2011;35:317–25 doi:10.1097/RCT.0b013e318213ccb0

    CrossRefPubMed
31. 31.↵
    1. Sasaki M,
    2. Yamada K,
    3. Watanabe Y, et al

    ; Acute Stroke Imaging Standardization Group-Japan (ASIST-Japan) Investigators. Variability in absolute apparent diffusion coefficient values across different platforms may be substantial: a multivendor, multi-institutional comparison study. Radiology 2008;249:624–30 doi:10.1148/radiol.2492071681 pmid:18936317

    CrossRefPubMed
32. 32.↵
    1. Tsujita N,
    2. Kai N,
    3. Fujita Y, et al

    . Interimager variability in ADC measurement of the human brain. Magn Reson Med Sci 2014;13:81–87 doi:10.2463/mrms.2012-0098 pmid:24769632

    CrossRefPubMed
33. 33.↵
    1. Wu CC,
    2. Jain R,
    3. Radmanesh A, et al

    . Predicting genotype and survival in glioma using standard clinical MR imaging apparent diffusion coefficient images: a pilot study from the Cancer Genome Atlas. AJNR Am J Neuroradiol 2018;39:1814–20 doi:10.3174/ajnr.A5794 pmid:30190259

    Abstract/FREE Full Text
34. 34.↵
    1. Harreld JH,
    2. Hwang SN,
    3. Qaddoumi I, et al

    . Relative ADC and location differ between posterior fossa pilocytic astrocytomas with and without gangliocytic differentiation. AJNR Am J Neuroradiol 2016;37:2370–75 doi:10.3174/ajnr.A4892 pmid:27469209

    Abstract/FREE Full Text
35. 35.↵
    1. McDonald CR,
    2. Delfanti RL,
    3. Krishnan AP, et al

    . Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma. Neuro Oncol 2016;18:1579–90 doi:10.1093/neuonc/now063 pmid:27106406

    CrossRefPubMed
36. 36.↵
    1. Rodriguez Gutierrez D,
    2. Manita M,
    3. Jaspan T, et al

    . Serial MR diffusion to predict treatment response in high-grade pediatric brain tumors: a comparison of regional and voxel-based diffusion change metrics. Neuro Oncol 2013;15:981–89 doi:10.1093/neuonc/not034 pmid:23585630

    CrossRefPubMed
37. 37.↵
    1. Poussaint TY,
    2. Vajapeyam S,
    3. Ricci KI, et al

    . Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol 2016;18:725–34 doi:10.1093/neuonc/nov256 pmid:26487690

    CrossRefPubMed